CARDINAL HEALTH INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Overview of Consolidated Results
| MD&A | Overview |
|---|
Overview of Consolidated Results
Revenue
Revenue increased 5 percent from the prior-year quarter to $67.5 billion due to branded and specialty pharmaceutical sales growth from existing customers.
GAAP and Non-GAAP Operating Earnings
| Three Months Ended September 30, | |||
|---|---|---|---|
| (in millions) | 2026 | 2025 | Change |
| GAAP operating earnings | $753 | $668 | 13% |
| Restructuring and employee severance | 23 | 20 | |
| Amortization and other acquisition-related costs | 182 | 104 | |
| Acquisition-related cash and share-based compensation costs | 94 | 64 | |
| Impairments and (gain)/loss on disposal of assets, net | (4) | 2 | |
| Litigation (recoveries)/charges, net | (47) | — | |
| Non-GAAP operating earnings | $1,001 | $857 | 17% |
GAAP operating earnings for the three months ended September 30, 2026 increased 13 percent from the prior-year quarter to $753 million, primarily due to the increased contributions from branded and specialty pharmaceutical products and the performance of our generics program, partially offset by an increase in acquisition-related costs.
Non-GAAP operating earnings for the three months ended September 30, 2026 increased 17 percent from the prior-year quarter to $1.0 billion, primarily due to the increased contributions from branded and specialty pharmaceutical products and the performance of our generics program.
GAAP and Non-GAAP Diluted EPS
| Three Months Ended September 30, | |||||
|---|---|---|---|---|---|
| ($ per share) | 2026 (2) | 2025 (2) | Change | ||
| GAAP diluted EPS (1) | $2.38 | $1.88 | 27% | ||
| Restructuring and employee severance | 0.07 | 0.06 | |||
| Amortization and other acquisition-related costs | 0.57 | 0.31 | |||
| Acquisition-related cash and share-based compensation costs | 0.38 | 0.26 | |||
| Impairments and (gain)/loss on disposal of assets, net | (0.01) | — | |||
| Litigation (recoveries)/charges, net | (0.13) | 0.03 | |||
| Non-GAAP diluted EPS (1) | $3.26 | $2.55 | 28% | ||
(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
GAAP diluted EPS for the three months ended September 30, 2026 increased 27 percent from the prior-year quarter to $2.38, primarily due to the factors impacting GAAP operating earnings in the preceding section and favorable changes in discrete tax items.
Non-GAAP diluted EPS for the three months ended September 30, 2026 increased 28 percent from the prior-year quarter to $3.26, primarily due to the factors impacting non-GAAP operating earnings in the preceding section and favorable changes in discrete tax items.
| 4 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.